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Abstract: Diabetes is one of the metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin 
action, or both. Type 2 diabetes, which accounts for ~90–95% of those with diabetes, the cause is a combination of resistance to insulin 
action and an inadequate compensatory insulin secretory response. Adequate glycemic control is thus one of the key factors to treat 
and/or reduce the diabetes and many plants have been used to reduce the glucose level by inhibiting the α-glucosidase that breaks down 
starch and disaccharides to glucose. Acorus calamus L (AC), a folk medicine to treat type 2 diabetes. In vitro α-glucosidase assay were 
carried out by measuring the release of p-nitrophenol, the insulin sensitizing activity, AC significantly decreased fasting serum glucose, 
and suppressed the increase of blood glucose levels after 2g/kg glucose loading in normal mice, in silico study showed that chemical 
compound on AC can inhibit α-glucosidase and the present study is designed to investigate the effects and molecular mechanisms of 
AC on glucagon-like peptide-1 (GLP-1) expression and secretion related to its hypoglycemic effects. 
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1. INTRODUCTION 
 
Diabetes mellitus is a syndrome of disordered 
metabolism, usually due to a combination of hereditary and 
environmental causes, resulting in hyperglycemia due to 
defects in either insulin secretion or insulin action in the 
body. Chronic hyperglycemia during diabetes causes 
glycation of body proteins that in turn lead to secondary 
complications affecting eyes, kidneys, nerves and arteries[1]. 
 
Diabetes mellitus (DM) is a common endocrine system 
disease that causes metabolic disorders and which leads to 
multiple organ damage syndrome. Clinical admiral diabetes 
is divided into two types, with more than 90% of patients 
having Type II diabetes [2]. The number of diabetes cases 
was 171 million in 2000 and is expected to rise to 366 million 
in 2030 [3]. Acting as a key enzyme for carbohydrate 
digestion, intestinal α-glucosidase is a glucosidase located at 
the epithelium of the small intestine. α- glucosidase has been 
recognized as a therapeutic target for the modulation of 
postprandial hyperglycemia, which is the earliest metabolic 
abnormality that occurs in Type 2 DM [4]. 
 
1.1.  Type 2 DM 
 
Type II diabetes is the major form of diabetes, accounting 
for approximately 90–95% of all diabetic cases. This form of 
diabetes usually begins with insulin insensitivity, a condition 
in which muscle, liver and fat cells do not respond to insulin 
properly. The pancreas eventually loses the ability to produce 
and secrete enough insulin in response to food intake. 
Gestational diabetes is caused by hormonal changes during 
pregnancy or by insulin insufficiency. Glucose in the blood 
fails to enter cells, thereby increasing the glucose level in the 
blood. High blood glucose, also known as hyperglycemia, 
can   damage   nerves   and   blood   vessels,   leading   to 
complications such as heart disease, stroke, kidney 
dysfunction, blindness, nerve problems, gum infections and 
amputation [5]. 
Type 2 diabetes mellitus is a complex, multifactorial 
disease. Oxidative stress has been suggested to be a 
contributory factor in development and complication of 
diabetes [6,7]. In recent years, natural antioxidants are used 
in dietary, pharmaceutical and cosmetic to replace synthetic 
antioxidants [8]. Research founded that some antioxidant 
compounds isolated and identified from medicinal plants had 
good  effect  on autoxidation  in  vitro  and  in  vivo  [9,10]. 
Postprandial  hyperglycemia  is the  most  important  health 
issue  in  the  21st   century.  α-Glucosidase  inhibitor reduce 
postprandial glucose level. Screening for potent natural 
glycosidase inhibitors is very important for diabetes [11]. 
 
1.2. Diagnostic criteria for diabetes 
 
The blood glucose levels of a healthy man are 80  mg/dLl on 
fasting and up to 160 mg/dL in the postprandial state. 
Diabetes mellitus is characterized by recurrent or persistent 
hyperglycemia, and is diagnosed by demonstrating one of 
the following : 
fasting plasma glucose level at or above 126 mg/dL or 7.0 
mmol/l.   plasma glucose at or above 200 mg/dL or 11.1 
mmol/L two hours after a 75 g oral glucose load in a glucose 
tolerance test. plasma glucose at or above 200 mg/dL or 11.1 
mmol/l.   Two fasting glucose measurements above 126 
mg/dL   or   7.0   mmol/l   or   random   blood   sugar   level 
>200mg/dL on two occasions is considered diagnostic for 
diabetes mellitus. Patients with fasting sugars between 6.1 
and 7.0 mmol/L (110 and 125 mg/dL) are considered to have 
imparied fasting glucose and patients with plasma glucose at 
or above 140 mg/dL or 7.8 mmol/L two hours after a 75 g
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 oral glucose load are considered to have impaired  glucose 
tolerance [2] 
 
2. TYPE 2 DIABETES MELLITUS MEDICATION 
 
After decades of research unraveling complex metabolic 
control networks, medicines capable of a safe reversal of type 
2 diabetes are still not available. Historically, complex 
diseases have repeatedly proven to be defiant to the best 
mono-therapeutic approaches. Several examples of 
combination    therapies    have    largely    overcome    such 
challenges, notably for the treatment of severe hypertension 
and tuberculosis. Obesity and its consequences, such as type 
2 diabetes, have proven to be equally resistant to therapeutic 
approaches based on single medicines. Appropriate 
management  of type 2  diabetes often requires adjunctive 
medications, and the recent registration of a few compound 
mixtures has set the precedent for combinatorial treatment of 
obesity. On the other hand, double or triple therapeutic 
combinations are  more difficult  to  advance to  regulatory 
approval.  Following  an  improved  understanding  of  the 
molecular basis for metabolic benefits following bariatric 
surgery interventions, several classes of novel unimolecular 
or independent combination therapeutics were discovered. 
These new classes of drug candidates are based on 
gastrointestinal hormones, offer efficacy superior to currently 
prescribed options and seem to have potential to fully reverse 
human obesity and type 2 diabetes. Moreover, gut peptide- 
based cell-specific targeted delivery of small molecules 
offers  additional  potential  for  novel  metabolic  precision 
medicines and reduced systemic side effects. In this 
presentation the discovery, pre-clinical validation and first 
clinical tests of peptide hormone poly-agonist drug 
candidates as well as of combinatorial single molecule 
therapeutic candidates will be summarized, including 
previously unpublished observations [16]. 
 
2.1. MECHANISM OF ANTIDIABETIC TERAPHY 
 
Western diabetic drugs correct hypoglycemia by 
supplementing insulin, improving insulin sensitivity, 
increasing insulin secretion from the pancreas and/or glucose 
uptake by tissue cells. Under normal conditions, pancreatic 
β-cells secrete sufficient insulin to maintain blood glucose 
concentration within a narrow range (72–126 mg/dL). The 
insulin stimulation followed by cascade signaling enhances 
glucose intake, utilization and storage in various tissues. In 
diabetic patients, the body loses insulin producing capacity as 
a result of pancreatic β-cell apoptosis or insulin insensitivity. 
The cytokines, lipo-toxicity and gluco-toxicity are three 
major stimuli for β- cell apoptosis [15] 
 
The treatments of diabetes include diet, exercise, use of 
oral hypoglycemic agents and insulin is the primary forms of 
treatment for diabetes. Currently available synthetic 
antidiabetic agents besides being expensive produce serious 
side effects. Apart from currently available therapeutic 
options, many herbal medicines have been recommended for 
the treatment of diabetes mellitus, medicinal plants have the 
advantage of having no side effects [13]. Traditional plant 
treatments have been used throughout the world for the 
therapy of diabetes mellitus. History showed that medicinal 
plants have been used in traditional healing around the world 
for a long time to treat diabetes; this is because such herbal 
plants have  hypoglycemic properties and  other beneficial 
properties, as reported in scientific literatures [14]. 
2.2. TRADITIONAL PLAT FOR ANTIDIABETIC 
 
Ethno pharmacological surveys indicate that more than 
1200 plants are used in traditional medicine for their alleged 
hypoglycemic activity [17]. Medicinal plants, since times 
immemorial, have been used in virtually all cultures as a 
source of medicine. A study of ancient literature indicates 
that diabetes was fairly well known and well-conceived as 
an entity in ancient India. The knowledge of the system of 
diabetes mellitus, as the history reveals, existed with the 
Indians since prehistoric age. Its earliest reference (1000 BC 
in the Ayurvedic literature) is found in mythological form 
where it is said to have originated by eating Havisha [2,18]. 
 
The NAPRALERT database lists over 1200 species of 
plants representing 725 genera in 183 families ex- tending 
from the marine algae and fungi with antidiabetic activity. 
Over half of these have been used ethno- pharmacologically 
in traditional medicine as antidiabetics, and some 50% of 
these traditional remedies have been studied experimentally 
[19]. The use of traditional medicine and medicinal plants in 
most developing countries, as a normative basis for the 
maintenance of good health, has been widely observed. 
Furthermore, an in- creasing reliance on the use of medicinal 
plants in the industrialized societies has been traced to the 
extraction and development of several drugs and 
chemotherapeutics from these plants as well as from 
traditionally used herbal remedies [2]. 
 
Certain herbs may lower blood glucose [20, 21]; 
however,  their  test  results are subject  to  several factors. 
Firstly, each herb contains thousands of components, only a 
few of which may be therapeutically effective [22]. 
Secondly, different parts of an herb have different ingredient 
profiles. Moreover, different extraction methods may yield 
different active ingredients. Thirdly, herbal formulae 
containing multiple herbs may have synergistic effects [15]. 
 
In Canada, following plants are used in the treatment of 
diabetes by the tribal people Abies balsamea (L.) Mill. 
Achillea millefolium L., Acorus calamus L., Aralia 
nudicaulis L., Aralia racemose L., Arisaema triphyllum (L.), 
Asarum canadense var. acuminatum Ashe, Celastrus 
scandens L., Cornus stolonifera Michx.,   Corylus cornuta 
Marsh.,   Dirca palustris L., Gaultheria procumbens L., 
Heracleum lanatum Michx., Juniperus communis L., 
Juniperus virginiana L., Kalmia angustifolia L.,   Ledum 
groenlandicum Oeder.,  Nuphar variegatum Durand,  Picea 
glauca (Moench) Voss., Picea mariana (Mill.), Populus 
balsamifera L.,   Populus tremuloides Michx., Prunus 
serotina Ehrh.,  Quercus alba L.,  Quercus rubra L.,  Rhus 
hirta f. typhina (L.),   Sassafras albidum (Nutt.) Ness., 
Smilacina racemosa (L.) Desf.,   Solidago canadensis L., 
Sorbus Americana Marsh, Taraxacum officinale Weber., 
Taxus canadensis Marsh., Thuja occidentalis L., Tsuga 
canadensis (L.) and Verbascum thapsus L [23,24]. 
 
Study from the Rhizomes of Acorus Calamus L. is 
widely used in the therapy of diabetes in traditional folk 
medicine of America [25] and it prevails in Merak, Banten, 
Indonesia to improve diabetes. However, the antidiabetic 
effects of Acorus Calamus L. have not been fully studied as 
yet. The hypolipidemic activity of Acorus Calamus L. in rats 
has been reported by Parab and Mengi [26].
 3. Acorus calamus L 
 
Acorus calamus L (AC), also known as ‘Vacha or Sweet 
flag’, it has been an important herb in the Ayurvedic medicine 
and indigenous medical system for over 100 years. AC 
rhizomes have been used as a single drug or as a component 
of certain compound drug preparations in the Indian 
Ayurvedic system of medicine for psychoneurosis, insomnia, 
hysteria, epilepsy and loss of memory [27, 28, 29]. It is also 
use  in  the  treatment  of cough,  fever,  bronchitis, 
inflammation, depression and other mental disorders, tumors, 
haemorrhoids, skin diseases, numbness and general debility 
[30], stimulant, emetic, carminative, stomachic, as antidotes 
for several poisoning [29].  AC can be found growing  in 
Central Asia or India, Central Europe and North America. In 
India it is common in areas that surround the Himalayas. 
Indian AC from the Jammu area is triploid and tetraploid; and 
The European as well as American variety of the AC is 
diploid [28, 29,31]. 
 
3.1. TAXONOMICAL CLASSICATION 
 
Kingdom             : Plantae 
Subkingdom        : Tracheobionta 
Superdivision      : Spermatophyta 
Division               : Magnoliophyta 
Class                    : Liliopsida 
Subclass              : Arecidae 
Order                   : Arales 
Family                 : Acoracae 
Genus                  : Acorus 
Species                : Acorus calamus L. [32] 
 
Part used: Roots and Rhizomes Synonyms: Sanskrit: Vacha, 
Sadgrantha;  English:   Calamus, Sweet  Flag;  Marathi: 
Vekhand; Hindi: Bach, Gorbach; Tamil: Vashambu; Telgu: 
Vadaja, Vasa; Bengal: Bach. Botanical description: Calamus 
is  a  semi  aquatic  herb  and  is  widely  distributed  by the 
edges of ponds and slow flowing waterways, growing  in 
shallow  water  or  in  a very  moist  loamy  soil.  Prefers  a 
pH  in the  range  5.5  to  7.5.  It  is  perennial  herb;  the 
rhizomes commonly occur in pieces about 5 to 15 cm in 
length and 1 to 2 cm  in thickness.  They are covered  with 
a   thin   brownish epidermis   and   cork   and   are   much 
shrunken, bearing brief longitudinal wrinkle. They are mark 
on the upper surface with large triangular  leaf scare that 
encircle the rhizome, springing from each side alternately; 
from these scars fibrous leaf trace bundle frequently project. 
The  under  surface  bears  an irregular zigzag line of small 
raised root scars that are circular and exhibit  a central stele 
surrounded by a narrow cortex. The rhizome breaks with 
a short corky fracture, and is pale brown or nearly white 
and  spongy  internally.  The  section exhibit  a  large  stele 
separated  by  a  yellowish  line,  the endodermis  from  a 
thick  cortex;  numerous  small,  oval, vascular  bundles  are 
scattered   thought    the   section.    The  freshly    fractured 
rhizome  has  an  agreeable  aromatic  odor. Leaves are right 
green having sword-shaped, based equitant, thickened in 
middle, margins wavy. Flowers are apeared in June and July 
and are yellow/green in color. The flowers are hermaphrodite 
(have  both  male  and  female  organs)  and  are pollinated 
by Insects [28, 29, 33]. 
 
 
 
a                                          b 
Figure 1. Acorus calamus L; Plant (a) Root (b) 
 
3.2. CHEMICAL CONSTITUEN 
A wide variety of chemical constituents have been reported 
from the rhizomes of AC. The oil of AC rhizomes has been 
analyzed by various workers for their chemical constituents. 
The oil was found to contain varying concentrations of a- 
asarone (1), b-asarone (2), c-asarone (3), calamene, 
calamenenol, calameone (4), a-pinene (5), b-pinene (6), 
camphene, p-cymene, eugenyl acetate, eugenol (7), 
isoeugenol (8), methyl isoeugenol (9), calamol, azulene (10), 
eugenol   methyl   ether,   dipentene   (11),   methyleugenol, 
asaronaldehyde  (12),  terpinolene  (13),  1,8-cineole  (14), 
camphor (15), a-caryophyllene (16), and hydrocarbons 
(Fig.1) The oil also contains fatty acids such as palmitic acid 
and  its ester, heptylic acid,  an ester of butyric  acid.first 
reported the synthesis of asarone from 1,2,4- 
trimethoxybenzene. Fractionation from the volatile oil by 
gas chromatography resulted in the isolation of a-asarone 
and b-asarone, which are the trans- and cis-isomers, 
respectively, of 2,4,5-trimethoxy-l-propenylbenzene. [33]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Phytoconstituents of Acorus calamus L.
 4. Acorus calamus L on TYPE 2 DIABETES 
MELLITUS MEDICATION 
Wu et al reported that ethyl acetate fraction of Acorus 
calamus L (ACE) but not other fractions of AC could 
enhance 3T3-L1 cells differentiation [35], they detected 
the effects of ACE on glucose consumption of L6 cells, 
which are sensitive to insulin. Their results shown in 
rosiglitazone enhanced glucose consumption of L6 cells 
in an insulin dependent manner (p < 0.01 vs. vehicle with 
insulin), whereas metformin elevated glucose 
consumption independent of insulin (p < 0.01 vs. vehicle 
either with or without insulin). 12.5 and 25 g/ml of ACE 
lowered the glucose of culture media in the presence but 
not in the absence of insulin (p < 0.05 and p < 0.01 vs. 
vehicle in the presence of insulin, p > 0.05 in the absence 
of insulin), and similar results were observed in 
rosiglitazone groups. ACE obviously increased insulin 
mediated glucose consumption in L6 skeletal muscle 
cells, suggesting that ACE may antagonize diabetes by 
improving the insulin sensitivity [36]. 
 
4.1. INSULIN SENSITIZING EFFECTS 
To confirm the insulin sensitizing effects of ACE in 
vivo, insulin resistant diabetic db/db mice were orally 
administrated for 3 weeks. As a result, the values of serum 
glucose in the different treated groups (10 mg/kg 
rosiglitazone, 100 mg/kg ACE, and 5 mg/kg rosiglitazone 
combined  with 100  mg/kg  ACE)  declined  by  40.1%, 
34.1% and 49% after 2 weeks, and by 70.1%, 54.5% and 
76.1% after  3 weeks,  comparing  with vehicle control 
respectively (p < 0.001). Serum triglyceride decreased 
significantly  in all treatment  groups after  1–3 weeks’ 
administration comparing with vehicle control. After 3 
weeks’ administration, 100 mg/kg ACE showed no 
significant influence to serum total cholesterol (p > 0.05), 
while 10 mg/kg rosiglitazone decreased it after 2 and 3 
weeks’ administration (p < 0.05), and a combination of 
100  mg/kg ACE and 5  mg/kg rosiglitazone markedly 
decreased total cholesterol after 3 weeks’ treatment (p < 
0.01). These results indicate that ACE depresses not only 
blood sugar but also triglyceride in obese diabetic mice, 
and  improves  the  lowering  effect  of total cholesterol 
caused by rosiglitazone [36]. 
 
4.2. INHIBITORY OF α-GLUCOSIDASE 
Our  investigation  showed  that  the  potency  of 
fraction n-butanol AC extract. as inhibitory agent on α- 
glucosidase enzyme. This study using the fraction from 
n-butanol AC extract. with column chromatography 
method to separated it. We use the resin to separated 
fraction because it suitable with the crude extract with 
high polarity (hydrophilic). The result of inhibition assay 
for α-glucosidase activity of   The result  of inhibition 
assay for α-glucosidase  from fraction show that the 5th 
fraction most active with IC50 value 4.87 µg ML-1 and the 
other fraction has not activity [37] 
Our investigation use a koji extract as control from 
Apergillus terreus is an especially prolific producer of 
secondary metabolites has biological activities such as 
inhibitory of α-glucosidase and it has a most potential 
activity therefore examined  the effect  on postprandial 
blood  glucose  level  after  a  meal  in  mice.  Triana’s 
research on inhibition mode koji extract against α- 
glucosidase was  investigated.  Inhibition  mode of koji 
extract had a combination of non-competitive and 
uncompetitive inhibition [38]. In their study inhibition 
mode of AC extract had a non-competitive inhibition, 
non-competitive inhibition of AC extract may be having 
different structure from the compound that has α- 
glucosidase inhibitory activity on competitive mode like 
acarbose [37]. On the next research we find that one of 
isolate from this fraction can inhibit the α-glucosidase 
with IC50 17.89 µg/mL [39]. For the additional research 
we have been use HPTLC method to find out the 
fingerprint of AC compound on leaf and rhizome. This 
research showed that β-asarone is the major compound on 
the leaf [40]. 
4.3. DECREASED FASTING SERUM GLUCOSE 
AC and ACE increased insulin secretion in HIT-T15 
cells as gliclazide did. As in vivo results, ACE (400 and 
800mg/kg) significantly decreased fasting serum glucose, 
and suppressed the increase of blood glucose levels after 
2g/kg glucose loading in normal mice. In addition, ACE 
as a mixed-type inhibitor inhibited alpha-glucosidase 
activity in vitro with an IC50 of 0.41μg/ml, and 100mg/kg 
of it clearly reduced the increase of blood glucose levels 
after 5g/kg amylum loading in normal mice. Apart from 
its insulin sensitizing effect, ACE may have 
hypoglycemic effects via mechanisms of insulin releasing 
and alpha-glucosidase inhibition, and thus improves 
postprandial hyperglycemia and cardiovascular 
complications [41]. 
 
4.4. IN SILICO STUDY 
Model of the enzyme α-glucosidase was obtained through 
the protein data bank with the code 1lwj in the donwload 
NCBI website. Models of chemical compounds contained 
in dringo (A. Calamus L) obtained through the site Take 
out  "jamu" Knapsack[42] and made in the formula 
structures of  2D  and  3D using  the  program  ACD  / 
Chemsketch.  Then  docking  used  Argus lab. Docking 
results as shown on  table 1 and figure 3 and  figure 4
 Tabel 1 Docking Results on AC Compound 
 
 
 
No Ligan / chemical compound Receptor  α-Glukosidase Free energy (∆H) Information 
1. (-)-Cadala-1,4,9-triene α-Glukosidase 0 (-) 
2. Ac ola mone α-Glukosidase 0 (-) 
3. Ac oradin α-Glukosidase 0 (-) 
4. Ac oragenmacrone α-Glukosidase 0 (-) 
5. Ac orenon α-Glukosidase 0 (-) 
6. Acorid acid α-Glukosidase -7,26053 kcal/mol (+) 
7. Ac orenene α-Glukosidase 0 (-) 
8. Aristolene α-Glukosidase 0 (-) 
9. Beta - acarone α-Glukosidase -7,62818 kcal/mol (+) 
10. Beta - Guanine α-Glukosidase 0 (-) 
11. Calacone α-Glukosidase -7,65883 kcal/mol (+) 
12. Calamusenone α-Glukosidase 0 (-) 
13. Calarene α-Glukosidase -2,9378 kcal/mol (+) 
14. 1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane α-Glukosidase -8,04385 kcal/mol (+) 
15. Delta - cadienene α-Glukosidase 0 (-) 
16. Apihsyobunon α-Glukosidase -7,74775 kcal/mol (+) 
17. Isoacolamone α-Glukosidase 0 (-) 
18. Isocaespitol α-Glukosidase -8,28388 kcal/mol (+) 
19. Isocalame ndiol α-Glukosidase 0 (-) 
20. Isoshyobunon α-Glukosidase 0 (-) 
21. Methylsoegenol α-Glukosidase -7,92367 kcal/mol (+) 
22. Preisocalamendiol α-Glukosidase 0 (-) 
23. Shyobunon α-Glukosidase -7,75501 kcal/mol (+) 
 
Note (+) : Inhibited Enzyme 
(-)  : Non InhibitedEnzyme 
 
 
 
Figure 3: 1-ethe nyl-1-methyl-2,4-di(prop-1-e n-2-yl)cyclohexane 
 
 
 
Figure 4 :  Isocaespitol
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Recently, In silico has play an important role in drug design 
and discovery. In which small molecule are virtually docked in 
to a drug target and the binding affinities are estimated using 
simplified  free energy calculation  method.  Many programs 
capable of carrying out virtual screening have been developed, 
most  of them are  pay ware.  One,  freely available docking 
software package potentially capable is ArgusLab. Argus lab 
was originally developed as molecular modeling software. It 
provides users with molecular building analyses, the ability to 
perform various molecular calculation and molecular structure 
visualization capabilities [43]. 
 
Molecular docking analysis capability was added to latest 
version of ArgusLab(ver.4.0.1). ArgusLab can be easily used 
even by beginner in computational docking and can run using 
windows (Microsoft Corp)[43].The enzyme α-glucosidase is 
the enzyme responsible for the conversion of carbohydrates 
into glucose. Carbohydrates are digested by enzymes in the 
mouth and intestines into simpler sugars which will then be 
absorbed into the body and improve blood sugar [44]. 
 
AC obtained several compounds such as Beta asarone, 
Acoradine,  Methylsoegenol,  1-ethenyl-1-methyl-2,4-di(prop- 
1-en-2-yl)cyclohexane,     Isocaespitol, Acoragermacrone, 
Preisocalamendiol, Shyobunon, Epishyobunone, Isocalamone, 
Acolamone, Aristolene, (-)-Cadala-1,4,9-triene, 
Isocalamendiol, Calacone, Beta-gualene, Calamusenon, 
Acoronene, Acorid  acid, Calarene, Acorenone through the site 
Take out "jamu" Knapsack and made in the formula structures 
of 2D and 3D using the program ACD / Chemsketch. Then 
docking  used  Argus  lab Program are  visualized  by Pymol 
program.Docking results showed activity in the compound 1- 
ethenyl-  1-methyl-2,4-at  (prop-1-en-2-yl)  Cyclohexane with 
free energy - 8.04385 kcal / mol, and the compound 
Isocaespitol with a free energy - 8.28388 kcal / mol. Chemical 
component that has the lowest free energy showed the most 
stable affinity that is expected to have good medicinal 
properties as well. Docking results showed activity in the 
compound 1-ethenyl- 1-methyl-2,4-at (prop-1-en-2-yl) 
Cyclohexane with free energy - 8.04385 kcal / mol, and the 
compound Isocaespitol with a free energy - 8.28388 kcal / mol 
[43]. 
 
4.5. MOLECULAR  MECHANISMS  ON  GLUCAGON- 
LIKE PEPTIDE-1 (GLP-1) 
 
ACE acts as an antidiabetic through insulin sensitizing, insulin 
releasing and alpha-glucosidase inhibitory activities. The 
present study is designed to investigate the effects and 
molecular  mechanisms  of ACE  on  glucagon-like  peptide-1 
(GLP-1) expression and secretion related to its hypoglycemic 
effects. The hypoglycemic effect of ACE (100mg/kg, i.g.) was 
confirmed by testing blood glucose levels or via oral glucose 
tolerance test (OGTT) in streptozotocin (STZ) induced 
hyperglycemic mice, db/db diabetic mice and diet-induced 
obese (DIO) mice. Plasma insulin, GLP-1 levels and intestinal 
GLP-1  related  gene  expression  were  determined  in  STZ- 
induced and db/db diabetic mice. The in vitro effects of ACE 
(12.5μg/ml) on the expression and secretion of GLP-1 were 
detected in NCI-H716 intestinal L-cells, and the correlation 
between ACE and molecules in the Wnt signaling pathway was 
further explored. 
 
ACE (100mg/kg) significantly lowered fasting blood glucose 
in STZ-induced and db/db diabetic mice and improved the 
OGTT in DIO mice. Insulin releasing and islet protective 
effects, along with the increased secretion of GLP-1, were 
observed. The expression of proglucagon gene (gcg) and post- 
translational processing gene prohormone convertase 3 (pc3) 
and the GLP-1 content in the culture medium of L-cells notably 
increased after the ACE treatment (12.5μg/ml). At the same 
time, β-catenin nuclear translocation occurred, and its 
downstream protein  cyclin  D1  was  activated,  showing  the 
involvement of Wnt signaling. ACE might activate Wnt 
signaling to increase the gene expression of gcg and pc3 and 
exert incretin effects, including insulinotropic and islet 
protection, to lower blood glucose levels via elevated GLP-1 
secretion either directly or indirectly [45]. 
 
CONCLUSION 
 
Acorus calamus L. have been proofed as folk medicine that 
can cure type 2 diabetes mellitus on many mechanism and can 
be use as antidiabetic related with many experiment methods. 
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